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Abstract 
Expanding research has shown, exposure to traumatic events increases the likelihood of 
developing a medical illness, mental disorder, substance use disorder, or comorbid conditions 
(Halter, 2014; Center for Behavioral Health Statistics and Quality, 2016; Child Welfare 
Information Gateway, 2013; National Institute of Mental Health, 2017). The Federal Drug 
Administration has approved medications for the treatment of alcohol use disorder, opioid use 
disorder and post-traumatic stress disorder (PTSD) symptoms; a medication for the treatment of 
methamphetamine use disorder, has yet to emerge (Perese, 2012; Stahl, 2013). The focus of 
research and this paper is to review current evidence on pharmacotherapy alone or in 
combination with psychotherapy, in the treatment of co-occurring stimulant use disorder 
methamphetamine-type and PTSD. Conducive to identifying all relevant studies, multiple 
bibliographic databases were used to complete a comprehensive search of evidence, including: 
MEDLINE, Pubmed, CINAHL, and PsycINFO.  Searched keyword phrases included: stimulant 
use disorder methamphetamine-type, PTSD, cooccurring disorder, pharmacotherapy, 
psychotherapy, and treatment outcomes. Databases’ own controlled vocabulary were used, when 
available, in performing the most inclusive search; preventing the chance of missing pertinent 
evidence. Resulting in 27 relevant pieces of evidence for critical appraisal. After critically 
appraising each study using CATmaker, the results were narrowed down to 14 of the most 
reliable and valid pieces of evidence used for synthesis including: 1 systematic review, level A; 
and 13, level B, randomized control trials. Modafinil, methadone, buprenorphine, N-
acetylcysteine (NAC), mirtazapine, dexamphetamine, and bupropion were associated with 
positive treatment outcomes for methamphetamine dependence. However, these studies were 
conducted in short time frames with small sample sizes. The research supports further 
investigation into these medications as the preliminary studies showed promising results. An 
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integrated treatment approach of psychotherapy in combination with pharmacotherapy, 
had the most significant results in adults with methamphetamine dependence (Shearer et 
al., 2009; Colfax et al., 2011). No evidence was identified for pharmacotherapy treatment 
of co-occurring stimulant use disorder methamphetamine-type and PTSD. Conducive to 
finding an effective treatment for this comorbidity, further research is required. 
Keywords: stimulant use disorder methamphetamine-type, PTSD, cooccurring 
disorder, pharmacotherapy, psychotherapy, and treatment outcomes 
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Background 
Exposure to traumatic events is common, ranging from 55% to 90% of adults in the 
United States, will experience at least one traumatic event in their lifetime (Halter, 2014; 
National Institute of Mental Health, 2017). However, among individuals with exposure to one or 
more traumatic events, only 8% develop PTSD (Halter, 2014; Center for Behavioral Health 
Statistics and Quality, 2016). Research has shown, exposure to traumatic events increases the 
likelihood of developing a medical illness, mental disorder, substance use disorder, or comorbid 
conditions (Halter, 2014; Center for Behavioral Health Statistics and Quality, 2016; Child 
Welfare Information Gateway, 2013; National Institute of Mental Health, 2017). 
While medications have been approved for the treatment of alcohol use disorder, opioid 
use disorder, and PTSD symptoms; the FDA has not approved any medications for the treatment 
of methamphetamine use disorder (Perese, 2012; Stahl, 2013). In 2016, an estimated 1,391,000 
or 0.5% of persons aged 12 and older in the United States, reported methamphetamine use in the 
past year (CDC, 2018). More than 10,721 Americans died from an overdose involving 
methamphetamine in 2017 (CDC, 2018). The rate of overdose deaths involving 
methamphetamine increased by 33.3% from 2015, with the highest rates found primarily in 
smaller towns and in midwestern and western states (CDC, 2018).  
The Substance Abuse and Mental Health Services Administration’s 2015 National 
Survey on Drug Use and Health reported, approximately 8.1 million adults (3.3 percent of all 
adults) in the United States had cooccurring mental health and substance use disorders in 2015 
(Center for Behavioral Health Statistics and Quality, 2016). The increasing number of illicit drug 
overdoses, deaths, and poorer treatment outcomes associated with this comorbidity elicits a 
review of literature relevant to the treatment outcomes of pharmacologic interventions alone or 
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in combination with psychotherapy of individuals with co-occurring PTSD and stimulant 
use disorder: methamphetamine-type.  
La Crosse County Health and Human Services’ Outpatient Mental Health and 
Substance Use Clinic serves an increasing population of individuals diagnosed with 
cooccurring mental health and substance use disorders in Wisconsin (Integrated Support 
& Recovery Services, 2018). During clinical practicum with La Crosse County this fall, a 
common theme emerged among patients diagnosed with substance use disorders (SUDs). 
Several of the patients had been exposed to at least one traumatic event in their lifetime. 
Below, used as an example of the patient population that could benefit from this review, 
is a case report of a patient seeking treatment for opioid use, methamphetamine use, and 
PTSD symptoms. 
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Chief Complaint: “I’m a heroin and meth addict. I need help with my cravings.”  
A 31-year-old female client presented for a psychiatric intake appointment seeking 
treatment for her addiction to methamphetamine and heroin. Information was obtained from 
patient and past medical records. Today, patient reported 30 days of sobriety.  Patient was 
serving an alternative to revocation from probation sentence, tracked by GPS and tested for drug 
and alcohol use. Patient reported her mood, thinking, and ability to concentrate had improved 
since being sober. Patient reported feeling hopeful for her future and recovery. Patient’s energy 
level was appropriate, not feeling fatigued or hyper throughout the day. Patient was motivated 
for treatment.  
Patient reported difficulty falling asleep and staying asleep, “I can’t shut my mind 
off, it just keeps running.” Patient endorsed restlessness in the evenings, “I have restlessness in 
my hands and legs at night.” Patient reported she used Gabapentin in the past to help with 
restlessness, sleep, methamphetamine and heroin cravings. Patient denied excessive anxiety or 
worry, “I’m nervous about the future but I would say it’s a normal level of anxiety.” Patient’s 
anxiety did not interfere with her ability to function. Patient denied mania and psychotic 
symptoms.   
Patient had a history of sexual abuse, a miscarriage and witnessing a suicide. Patient 
reported she had frequent flash backs, relived the traumatic moments, had nightmares once every 
few weeks, and was afraid to go to sleep. Patient reported some hypervigilance, but believed it 
was related to her substance use.  
Patient’s strengths included a good family support system, motivated and determined in 
her recovery. Patient reported she was working on trying to think more positively. Patient 
enjoyed creating art.   
 PHARMACOTHERAPY FOR PTSD AND METHAMPHETAMINE USE 
 
8 
Patients goals were to: maintain sobriety, change mind set to think more 
positively, express herself with art, and learn more coping skills to manage 
PTSD symptoms and drug cravings.     
Previous psychotropic medication trials included: Gabapentin, Prozac and 
Vivitrol injection. Patient had no previous inpatient psychiatric hospitalizations.  Patient 
denied history of suicide attempts.  
Patient had attended an intensive outpatient treatment program for heroin and 
methamphetamine use, in the past. Patient was currently receiving therapy services at a 
local program designed to help individuals with mental health issues and substance 
abuse.  
Patient’s past medical history included diagnoses of Opioid Use Disorder and 
Hepatitis C. Patient was having regular menstrual periods, was not taking birth control, 
but was not currently sexually active. Patient had been pregnant once, but miscarried at 6 
weeks gestation. Last physical and set of labs had not been completed for a few years. 
Patient was going to see her primary care physician that day. Patient had no known drug 
allergies.  
Patient was born in the Midwest, where she was raised, and had one brother. 
Patient’s parents divorced when she was a teenager.  Both parents were in serious 
relationships with someone new. Patient was an average student and graduated high 
school. Patient was married at age 19 and recently divorced her husband. They used to 
use methamphetamine and heroin together. Patient’s brother-in-law 
committed suicide. Patient’s father had alcoholism. Her brother was addicted to “K2” and 
had ADHD. Patient was unemployed but had been employed at various places 
previously.  
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Patient was alert, fully attentive, casually dressed and groomed.  Appeared average 
weight and stated age. Attitude was cooperative and not guarded. Activity was calm, not restless, 
no abnormal movements, good eye contact. Patient was fully oriented, memory intact. Mood was 
“good, better.” Affect was within normal range, not restricted, flat or labile. Normal expressive 
and receptive language function. Thought process was organized, goal directed, and did not 
require redirections. Thought content was free from delusions, suicidal and homicidal ideation. 
Patient was not attending to internal stimuli. Patient had good insight and judgment appeared to 
be improving with sobriety. Patient had a normal gait and station; no tics or tremors were 
observed.  
Records and labs will be reviewed from primary care visit. A follow-up appointment was 
made for 6 weeks out. Preliminary psychiatric diagnoses given include: opioid use disorder, 
stimulant use disorder: methamphetamine-type, PTSD rule out acute stress disorder. 
Psychotropic medications prescribed were Vivitrol 380 mg intramuscular every 28 days and 
gabapentin 300 mg by mouth three times a day as needed for restlessness. 
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A Literature Review of Pharmacotherapy Treatment Outcomes for Comorbid Post-Traumatic 
Stress Disorder and Methamphetamine Use 
What is the evidence that pharmacotherapy alone or in combination with 
psychotherapy, improves treatment outcomes in adults diagnosed with cooccurring 
stimulant use disorder methamphetamine-type and post-traumatic stress disorder?  
Method 
The strongest level of evidence, Level A, consists of a meta-analysis of multiple 
controlled studies or a meta-synthesis of qualitative studies with results that consistently 
support a specific action, intervention or treatment (Armola et al., 2009). The primary 
focus of the research would revolve around finding level A studies. However, if level A 
evidence was not available, the next level of evidence down the ANCC’s hierarchy of 
evidence, level B, would be used. Level B evidence consists of well-designed controlled 
studies, both randomized and nonrandomized, with results that consistently support a 
specific action, intervention, or treatment (Armola et al., 2009). Continuation down the 
hierarchy would be utilized as needed. 
Conducive to identifying all relevant studies, multiple bibliographic databases 
were used to complete a comprehensive search of evidence. The databases used include: 
MEDLINE, Pubmed, CINAHL, and PsycINFO. MEDLINE is the largest health database, 
covering over 5,000 journals and other publication types in all areas of health sciences; 
therefore, increasing the likelihood of identifying significant evidence (Foreman & 
Mateo, 2014). Cumulative Index to Nursing and Allied Health Literature, CINAHL, 
provides coverage of 5,000 journals as well as 80 other document types (Foreman & 
Mateo, 2014).  PsycINFO, a large behavioral science and mental health database 
produced by the American Psychological Association and containing more than 3 million 
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records from 2,500 journals, books, book chapters and dissertation (Foreman & Mateo, 2014). In 
order to warrant the most thorough and relevant results, it was essential for the databases used in 
the literature review to cover both healthcare and mental health studies. 
Searched keyword phrases included: stimulant use disorder methamphetamine-type, 
PTSD, cooccurring disorder, pharmacotherapy, therapy, and treatment outcomes. Databases’ 
own controlled vocabulary was used, when available, in performing the most inclusive search; 
preventing the chance of missing pertinent evidence.  
MEDLINE and Pubmed databases were searched using Medical Subject Headings or 
MeSH terms from the National Library of Medicine’s controlled vocabulary for MEDLINE 
(Fink, 2014; Foreman & Mateo, 2014). Using MeSH, the keyword phrase, stimulant use disorder 
methamphetamine-type, was searched, producing no results. No results were found using 
Pubmed. Next, keyword phrase methamphetamine use disorder, was searched using MeSH, 
which produced the MeSH match term of “methamphetamine.” A Pubmed database search of 
methamphetamine produced an overwhelming 8,942 articles. However, a Pubmed database 
search of MeSH terms methamphetamine and pharmacology with Boolean connector “AND,” 
narrowed results down to 6,180 articles. Continuing with the same search method of one 
keyword phrase at a time, using the database-controlled vocabulary, MeSH, then combining the 
searches using the Boolean “AND.” A Pubmed database search of MeSH terms, 
“methamphetamine” “pharmacology” “treatment outcomes” “mental disorders” connected with 
Boolean connector “AND” with limitations of English, humans, and published within the past 10 
years; produced 46 articles. Additional combinations of the keyword phrases, “therapy” “post-
traumatic stress disorder” produced no results.  
Next, it was necessary to determine if any of the 46 articles discovered were meta-
analysis, the highest level of evidence. Once the meta-analysis filter was applied to the results, 
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one article remained. In order to obtain more results, another filter of randomized 
controlled trials was applied and a total of 21 articles remained.  
Cumulative Index to Nursing and Allied Health Literature, CINAHL, database 
uses a different controlled vocabulary, called CINAHL Subject Headings (Fink, 2014; 
Foreman & Mateo, 2014) Keyword phrases and matching terms from CINAHL Subject 
Headings were searched in a variety of combinations. Unfortunately, many of the 
searches produced zero results. However, the combination of “treatment outcome” 
“methamphetamine” and “pharmacological treatment” using the Boolean connector 
“AND” produced 4 articles with the limitations of full text, academic journals and peer 
reviewed.  3 of the 4 articles were applicable to answering the research question.  
Next, using PsycINFO’s thesaurus, each keyword phrase and matching key terms 
from the thesaurus were searched independently. Different combinations of keyword 
phrases were used in order to thoroughly search for most significant results. Ultimately, 
the combination of “methamphetamine” AND “dual diagnosis” AND “treatment 
outcomes” AND “pharmacological” yielded the most results. After applying filter 
limitations of peer reviewed, full text, academic journal and published within the last 8 
years; 2 articles remained and were kept for analysis.  
Total, 26 pieces of evidence were identified using Pubmed, MEDLINE, CINAHL, 
and PsycINFO’s databases. As a final step in the identification process, using the 
ancestry method, a hand search of the reference lists of each remaining study was 
conducted; in search of relevant studies that might not have been found in the original 
search (Fink, 2014; Foreman & Mateo, 2014). One additional article was discovered, 
resulting in 27 relevant pieces of evidence used for critical appraisal. No duplicate 
articles were identified.  
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CATmaker, an online appraisal tool available through Centers for Evidence-Based 
Medicine, was used to critically appraise each article. After performing a rapid critical appraisal 
of each article, a total of 13 reliable and valid studies had met inclusion criteria. Consisting of 
one level A piece of evidence, a systematic review; and 13, level B pieces of evidence which 
were randomized control trials. All 14 pieces of evidence were used in this synthesis of 
literature. 
Results 
In a randomized, double-blind, placebo-controlled trial, Shearer et al., found modafinil 
200/mg a day, associated with a reduction in methamphetamine use among methamphetamine 
dependent patients (2009). Those who participated in psychotherapy showed better outcomes, as 
well as, those who did not have comorbidities (Shearer et al., 2009).  
Methadone and buprenorphine have been approved by the FDA for treatment of opioid 
use disorder (Stahl, 2017).  In a randomized control study, the efficacy of methadone and 
buprenorphine in the treatment of methamphetamine withdrawal cravings were examined. Both 
medications were effective in reducing methamphetamine use cravings (Ahmadi & Jahromi, 
2017). However, those treated with buprenorphine showed significantly more reduction in 
cravings compared to those treated with methadone (Ahmadi & Jahromi, 2017).  Salehi, 
Emadossadat, Kheirabadi, Maracy, and Sharbafchi also found buprenorphine to be effective in 
significantly reducing methamphetamine use cravings among individuals addicted to 
methamphetamine in a randomized, double-blind, placebo-controlled trial (2015).  
A randomized, double-blind, placebo-controlled clinical trial of the amino acid, N-
acetylcysteine (NAC), showed good efficacy in suppressing methamphetamine use cravings, in 
methamphetamine use dependence (Seyed, Ghafur, Mousavi et al., 2015). A randomized 
controlled study showed the addition of mirtazapine to psychotherapy, decreased 
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methamphetamine uses among active methamphetamine users (Colfax et al., 2011). A 
reanalysis of a multisite, double-blind, placebo-controlled trial showed bupropion to be 
effective in facilitating the achievement of abstinence of methamphetamine use amongst 
methamphetamine dependent individuals (McCann & Li, 2012).  
The pharmacotherapy treatment effects of once-daily dosing of dexamphetamine 
sustained release in individuals with methamphetamine use disorder were analyzed in a 
randomized controlled trial (Longo et al., 2010). The results were measured by self-report 
and hair analysis. Those treated with dexamphetamine, self-reported decrease in 
methamphetamine use; hair analysis was used to confirm this finding (Longo et al., 
2010). The use of daily dexamphetamine showed increased treatment retention, decreased 
methamphetamine use, decreased dependence and decreased withdrawal symptom 
(Longo et al., 2010). However, there was not a significant difference between the placebo 
group and the dexamphetamine treated group (Longo et al., 2010). The study supports 
further research on pharmacotherapy as a treatment intervention for methamphetamine 
dependence. (Longo et al., 2010).   
A systematic review and meta-analysis of randomized, placebo-controlled trials 
by Kishi, Matsuda, Iwata, and Correll showed no advantages of antipsychotics over the 
placebo in psychostimulant abstinence or cravings (2013). Antidepressants were found to 
be ineffective in the treatment of methamphetamine use disorder in a randomized 
controlled trial by Hellem, Lundberg, and Renshaw (2015). Briones et al., hypothesized 
in a randomized double-blind phase II clinical trial, that varenicline, a nicotine receptor 
partial agonist, would be effective treatment for methamphetamine dependence due to the 
dopaminergic effects (2018). However, the study showed varenicline to be ineffective in 
treating methamphetamine use (Briones et al., 2018). 
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A multisite randomized clinical trial showed improved patient outcomes using 12-step 
sponsors among individuals receiving treatment for stimulant use disorder. (Wendt, Hallgren, 
Daley, & Donovan, 2017). Neurofeedback plus pharmacotherapy was shown to be more 
effective then pharmacotherapy alone in the of treatment of crystal methamphetamine dependent 
patients (Rostami & Dehghani-Arani, 2015). Longer durations of contingency management in 
conjunction with psychosocial treatment was found to be effective in abstaining from 
methamphetamine use among methamphetamine dependent individuals in a randomized control 
trial by Roll, Chudzynski, Cameron, Howell, and McPherson (2013). 
Discussion 
Modafinil, methadone, buprenorphine, N-acetylcysteine (NAC), mirtazapine, 
dexamphetamine, and bupropion were associated with positive treatment outcomes amongst 
individuals with methamphetamine dependence as evidence by decreased cravings to use meth 
and longer periods of abstaining from methamphetamine use (Ahmadi & Jahromi, 2017; Salehi 
et al., 2015; Shearer et al., 2009; Seyed, Ghafur, & Mousavi et al., 2015; Colfax et al., 201; 
McCann & Li, 2012; Longo et al., 2010). An integrated treatment approach of psychotherapy in 
combination with pharmacotherapy, had the most significant results in adults with 
methamphetamine dependence (Shearer et al., 2009; Colfax et al., 2011). Neurofeedback, 
sponsorship, and longer durations of contingency management in conjunction with 
pharmacotherapy, showed improved treatment outcomes amongst adults seeking treatment for 
stimulant use disorder (Wendt et al., 2017; Rostami & Dehghani-Arani, 2015; Roll, Chudzynski, 
Cameron, Howell, & McPherson, 2013). Antipsychotics, antidepressants and varenicline, 
showed to be ineffective in treatment of methamphetamine use (Kishi et al., 2013; Hellem, 
Lundberg, & Renshaw, 2015; Briones et al., 2018). 
 
Limitations of These Studies  
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Several of the randomized controlled trials studying the efficacy of pharmacotherapy in 
individuals with methamphetamine use disorder, analyzed in this literature review; were faced 
with many barriers and limitations. Sample sizes were too small, many participants dropped out 
of the studies related to their substance use, difficulty of monitoring medication compliance 
amongst the control groups and mediating factors such as severity or duration of use that could 
may influence results, were not controlled. Scarce literature on treatment of comorbidities was 
identified. Multiple searches yielded no results with the addition of keyword phrases of 
comorbidity, trauma, and post-traumatic stress disorders; showing a lacking amount of evidence 
pertaining to the treatment of cooccurring stimulant use disorder: methamphetamine-type and 
post-traumatic stress disorder. 
Conclusions and Future Study 
An insufficient amount of literature is available on the treatment of cooccurring 
stimulant use disorder: methamphetamine-type and post-traumatic stress disorder 
supports my recommendation for further research on the treatment of this comorbidity. 
Despite years of effort and several randomized controlled trials, an effective medication 
for the treatment of methamphetamine dependence, has yet to emerge. While modafinil, 
methadone, buprenorphine, N-acetylcysteine (NAC), mirtazapine, dexamphetamine, and 
bupropion have been associated with positive treatment outcomes amongst individuals 
with methamphetamine dependence as evidence by decreased cravings to use 
methamphetamine and longer periods of abstaining from methamphetamine use; these 
studies were conducted in short time frames with small sample sizes. The research 
supports further investigation into these medications as preliminary studies show 
promising results.  
 
 PHARMACOTHERAPY FOR PTSD AND METHAMPHETAMINE USE 
 
17 
References 
Ahmadi, J., & Jahromi, L. R. (2017). Comparing the effect of buprenorphine and methadone in the 
reduction of methamphetamine craving: A randomized clinical 
trial. Trials, 18 doi:10.1186/s13063-017-2007-3 
Armola, R. R., Bourgault, A. M., Halm, M. A., Board, R. M., Bucher, L., Harrington, L., . . . 
Medina, J. (2009). AACN levels of evidence: What's new? Critical Care Nurse, 29(4), 70-
73. doi:10.4037/ccn2009969 
Briones, M., Shoptaw, S., Cook, R., Worley, M., Swanson, A., Moody, D. E., . . . Heinzerling, K. 
(2018). Varenicline treatment for methamphetamine dependence: A randomized, double-
blind phase II clinical trial. Drug and Alcohol Dependence, 189, 30-36. 
doi:10.1016/j.drugalcdep.2018.04.023 
CDC National Center for Injury Prevention and Control. (2018). 2018 annual surveillance report of 
drug-related risks and outcomes. Atlanta, Georgia: Surveillance Special Report. Centers for 
Disease Control and Prevention. Retrieved 
from https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf 
Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends 
in the united states: Results from the 2014 national survey on drug use and health.  1 Choke 
Cherry Road, Rockville, MD 20857: United States Department of Health and Human 
Services Publication No. SMA 15-4927, NSDUH Series H-50. Retrieved 
from https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-
2014.pdf 
Center for Behavioral Health Statistics and Quality. (2016). Correlates of lifetime exposure to one 
or more potentially traumatic events and subsequent posttraumatic stress among adults in 
the united states: Results from the mental health surveillance study, 2008-2012. United 
 PHARMACOTHERAPY FOR PTSD AND METHAMPHETAMINE USE 
 
18 
States: Retrieved from https://www.samhsa.gov/data/report/correlates-lifetime-exposure-
one-or-more-potentially-traumatic-events-and-subsequent 
Child Welfare Information Gateway. (2013). What is child abuse and neglect? recognizing the signs 
and symptoms. Retrieved from https://www.childwelfare.gov/pubs/factsheets/whatiscan/ 
Colfax, G. N., Santos, G., Das, M., Santos, D. M., Matheson, T., Gasper, J., . . . Vittinghoff, E. 
(2011). Mirtazapine to reduce methamphetamine use: A randomized controlled 
trial. Archives of General Psychiatry, 68(11), 1168-1175. 
doi:10.1001/archgenpsychiatry.2011.124 
Halter, M. J. (2014). Varcarolis' foundations of psychiatric mental health nursing: A clinical 
approach (7 ed. ed.). US: Elsevier Saunders. 
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015). A review of treatment options for co-
occurring methamphetamine use disorders and depression. Journal of Addictions 
Nursing, 26(1), 14-23. doi:10.1097/JAN.0000000000000058 
Integrated Support & Recovery Services. (2018). La crosse county human services department. 
Retrieved from http://www.co.la-crosse.wi.us/humanservices/integrated.asp 
Kishi, T., Matsuda, Y., Iwata, N., & Correll, C. U. (2013). Antipsychotics for cocaine or 
psychostimulant dependence: Systematic review and meta-analysis of randomized, placebo-
controlled trials. The Journal of Clinical Psychiatry, 74(12), e1180. 
doi:10.4088/JCP.13r08525 
Longo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. M. (2010). Randomized 
controlled trial of dexamphetamine maintenance for the treatment of methamphetamine 
dependence. Addiction, 105(1), 146-154. doi:10.1111/j.1360-0443.2009.02717.x 
 PHARMACOTHERAPY FOR PTSD AND METHAMPHETAMINE USE 
 
19 
Magdalena Mateo PhD, R N, & Marquis Foreman PhD, R N. (2014). Research for advanced 
practice nurses, second edition (Second edition. ed.). New York: Springer Publishing 
Company. 
McCann, D. J., & Li, S. (2012). A novel, nonbinary evaluation of success and failure reveals 
bupropion efficacy versus methamphetamine dependence: Reanalysis of a multisite 
trial. CNS Neuroscience & Therapeutics, 18(5), 414-418. doi:10.1111/j.1755-
5949.2011.00263.x 
National Institute of Mental Health. (2017). Post-traumatic stress disorder. Retrieved 
from https://www-nimh-nih-gov.ezproxy.library.und.edu/health/statistics/post-traumatic-
stress-disorder-ptsd.shtml 
National Institute on Drug Abuse: Advancing Addiction Science. (2018). Overdose death rates. 
Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-
rates 
Perese. (2012). Psychiatric advanced practice nursing A biopsychosocial foundation for practice. 
Philadelphia: F. A. Davis Company. Retrieved from http://lib.myilibrary.com?ID=425276 
Roll, J. M., Chudzynski, J., Cameron, J. M., Howell, D. N., & McPherson, S. (2013). Duration 
effects in contingency management treatment of methamphetamine disorders. Addictive 
Behaviors, 38(9), 2455. doi:10.1016/j.addbeh.2013.03.018 
Rostami, R., & Dehghani-Arani, F. (2015). Neurofeedback training as a new method in treatment of 
crystal methamphetamine dependent patients: A preliminary study. Applied 
Psychophysiology and Biofeedback, 40(3), 151-161. doi:10.1007/s10484-015-9281-1 
Salehi, M., Emadossadat, A., Kheirabadi, G. R., Maracy, M. R., & Sharbafchi, M. R. (2015). The 
effect of buprenorphine on methamphetamine cravings. Journal of Clinical 
Psychopharmacology, 35(6), 724-727. doi:10.1097/JCP.0000000000000408 
 PHARMACOTHERAPY FOR PTSD AND METHAMPHETAMINE USE 
 
20 
Seyed Ghafur Mousavi, Mohammad Reza Sharbafchi, Mehrdad Salehi, Mohammad Peykanpour, 
Naeemeh Karimian Sichani, & Mohammad Maracy. (2015). The efficacy of N-
acetylcysteine in the treatment of methamphetamine dependence: A double-blind controlled, 
crossover study. Archives of Iranian Medicine, 18(1), 28. Retrieved from https://search-
proquest-com.ezproxy.library.und.edu/docview/1644151612 
Shearer, J., Darke, S., Rodgers, C., Slade, T., Beek, I., Lewis, J., . . . Wodak, A. (2009). A double-
blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine 
dependence. Addiction, 104(2), 224-233. doi:10.1111/j.1360-0443.2008.02437.x 
Stahl, S. (2013). Stahl's essential psychopharmacology : Neuroscientific basis and practical 
applications (4th ed.) Cambridge University Press.  
Stahl, S. (2017). Stahl's essential psychopharmacology prescriber's guide; (6th ed.). Cambridge 
University Press. 
Wendt, D. C., Hallgren, K. A., Daley, D. C., & Donovan, D. M. (2017). Predictors and outcomes of 
twelve-step sponsorship of stimulant users: Secondary analyses of a multisite randomized 
clinical trial. Journal of Studies on Alcohol and Drugs, 78(2), 287. 
doi:10.15288/jsad.2017.78.287 
